InterveXion Therapeutics
UAMS’ InterveXion Gets Another $13.8M for Drug Therapy Trials
The federal grant money will fund a mid-stage clinical trial of a drug that could help meth users break their addiction. read more >
Keith Ward to Lead Little Rock’s InterveXion Therapeutics
InterveXion Therapeutics of Little Rock, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, announced Monday the appointment of Keith Ward, Ph.D., to president and CEO. read more >
UAMS Startup Receives $14.5M to Help Drug Users Break Addiction
InterveXion Therapeutics LLC, a University of Arkansas for Medical Sciences BioVentures startup company, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction. read more >
Sign up for Daily E-news
Sign Up
THIS WEEK’S EDITION
This Week’s Stories
View Digital Edition
